Spring is almost here, and before we know it, it will be time for FACTOR 2026! Registration is now open for our annual conference. This month, our OutBidding Osteosarcoma auction is live — a fun way to support MIB Agents while bidding on exciting items and experiences. This month, we are excited to spotlight members of our 2026 Junior Advisory Board and NextGen community, along with opportunities to apply for travel awards, share treatment experiences, and take part in conversations that help researchers, families, and surgeons learn from one another. We are excited to share that Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy), a novel target radiopharmaceutical clinical trial for unresectable relapsed/refractory osteosarcoma, is now open at UCLA, enrolling patients ages 18+ (with plans to expand to younger patients after initial safety evaluation), and offering financial assistance for travel.
With hope,
The MIB Agents Team
.png)
.png)
Since 2017, the annual MIB Agents FACTOR Conference has brought together leading researchers, clinicians, surgeons, patient families, and OsteoWarriors (survivors, patients, and siblings of OsteoWarriors and OsteoAngels) — all working together to Make It Better for those facing osteosarcoma. FACTOR stands for Funding, Awareness, Collaboration, Trials, Osteosarcoma, and Research — driving collaboration, advancing treatments, and improving outcomes for patients.
This June, join us in Columbus for our 9th Annual FACTOR Conference!
The MIB Agents Junior Advisory Board and NextGen members play a vital role in our community. They help shape the direction of programs, education, advocacy, and research, ensuring that the voices of OsteoWarriors and families remain at the center of our work. We are excited to welcome our 2026 JAB and NextGen group, and cannot wait to see the meaningful progress they will make this year.
Learn More About 2026 JAB and NextGen Members
Get ready for our sixth annual OutBidding Osteosarcoma auction, featuring exclusive items and unforgettable experiences! Our generous donors, who Make It Better for kids with osteosarcoma, have contributed one-of-a-kind treasures across Original Art, Home Goods & Beauty, and Unique Experiences.
Share the auction with your family, friends, and community—together, we can Make It Better!
Bidding opens: March 16 at 5:00 PM ET
Bidding closes: March 30 at 5:00 PM ET
If you have a job posting and you would like it included here, please email christina@mibagents.org.
The CU Anschutz Sarcoma Program is excited to announce the second annual Rocky Mountain Sarcoma Symposium! The event will be held in Boulder, CO, at the Limelight Hotel on April 17th and 18th, 2026. The emphasis of the 2026 program is basic, translational, and clinical sarcoma care and will include an impressive lineup of lecturers from the University of Colorado, Children's Hospital Colorado, and Colorado State University, as well as nationally recognized guest lecturers. CME credit will be provided. View the agenda. If you have any questions, please contact Maureen Gaeke at maureen.gaeke@cuanschutz.edu.
MIB Agents is offering a limited number of travel awards for FACTOR 2026 (June 25–27, Columbus, OH) for researchers, physicians, and OsteoWarriors. OsteoWarriors can be nominated for a travel award by social workers, child life specialists, or medical professionals.
Learn More About Travel Awards
MIB Agents is inviting patients and families to contribute their treatment experiences to CURE-ID, a free global website and mobile app designed to advance research in rare cancers like osteosarcoma. By sharing your treatment history, whether you are in treatment, NED, or a bereaved caregiver, you can help identify promising, ineffective, or harmful therapies and inform future clinical trials and drug repurposing.
Participation is simple: patients or care partners complete a brief survey about diagnosis, treatments, and outcomes. All information is anonymous, and shared data is publicly available to help researchers and families learn from one another.
CURE-ID staff are available to support participants in entering their experiences. Join us in strengthening the osteosarcoma community’s collective knowledge and submit your case by March 10th. Questions? Contact heather.stone@fda.hhs.gov or karen.kwok@nih.gov.
Share Your Treatment Experience with CURE-ID
Have you talked with a surgeon about cancer care decisions? Share your experience with a research team at the University of Alabama at Birmingham that is studying how patients with cancer experience conversations with their surgeons about what matters most to them when making treatment decisions. Eligible participants include Adults (18+) who were diagnosed with cancer in the past 2 years and have met with a surgeon about possible cancer surgery. The brief 10-minute anonymous survey covers the following topics:
- How treatment decisions were discussed
- Whether your personal priorities and values were addressed
- What helped or made those conversations harder
Your experiences can help improve how surgeons communicate with patients.
.png)
